BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab (provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer. For additional information on BriaCell, please visit our website: http://briacell.com/
View Top Employees from BriaCell Therapeutics Corp.Website | http://www.briacell.com |
Ticker | BCT |
Revenue | $6 million |
Employees | 20 (19 on RocketReach) |
Founded | 2004 |
Address | 2929 Arch St 3rd Floor, Philadelphia, Pennsylvania 19104, US |
Phone | (604) 921-1810 |
Fax | (604) 921-1898 |
Technologies |
JavaScript,
HTML,
PHP
+24 more
(view full list)
|
Industry | Business Services, Biotechnology, Biotechnology Research, Immunotherapy, Science and Engineering, Breast Cancer, Medical, Health Care, Cancer Vaccines |
Web Rank | 10 Million |
Keywords | Briacell, Bria Cell |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 541714 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies |
Looking for a particular BriaCell Therapeutics Corp. employee's phone or email?
The BriaCell Therapeutics Corp. annual revenue was $6 million in 2024.
Giuseppe Del Priore is the Chief Medical Officer of BriaCell Therapeutics Corp..
19 people are employed at BriaCell Therapeutics Corp..
BriaCell Therapeutics Corp. is based in Philadelphia, Pennsylvania.
The NAICS codes for BriaCell Therapeutics Corp. are [541714, 54171, 54, 541, 5417].
The SIC codes for BriaCell Therapeutics Corp. are [87, 873].